EP2012796A4 - Verwendung eines glucocorticoidrezeptor-ii-antagonisten zur behandlung von depressionen bei mit il-2 behandelten patienten - Google Patents

Verwendung eines glucocorticoidrezeptor-ii-antagonisten zur behandlung von depressionen bei mit il-2 behandelten patienten

Info

Publication number
EP2012796A4
EP2012796A4 EP07783115A EP07783115A EP2012796A4 EP 2012796 A4 EP2012796 A4 EP 2012796A4 EP 07783115 A EP07783115 A EP 07783115A EP 07783115 A EP07783115 A EP 07783115A EP 2012796 A4 EP2012796 A4 EP 2012796A4
Authority
EP
European Patent Office
Prior art keywords
antagonist
glucocorticoid receptor
patients taking
treat depression
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07783115A
Other languages
English (en)
French (fr)
Other versions
EP2012796A2 (de
Inventor
Joseph K Belanoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of EP2012796A2 publication Critical patent/EP2012796A2/de
Publication of EP2012796A4 publication Critical patent/EP2012796A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
EP07783115A 2006-05-02 2007-05-02 Verwendung eines glucocorticoidrezeptor-ii-antagonisten zur behandlung von depressionen bei mit il-2 behandelten patienten Withdrawn EP2012796A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79726506P 2006-05-02 2006-05-02
PCT/US2007/068044 WO2007131041A2 (en) 2006-05-02 2007-05-02 The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2

Publications (2)

Publication Number Publication Date
EP2012796A2 EP2012796A2 (de) 2009-01-14
EP2012796A4 true EP2012796A4 (de) 2010-08-11

Family

ID=38668513

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07783115A Withdrawn EP2012796A4 (de) 2006-05-02 2007-05-02 Verwendung eines glucocorticoidrezeptor-ii-antagonisten zur behandlung von depressionen bei mit il-2 behandelten patienten

Country Status (5)

Country Link
EP (1) EP2012796A4 (de)
JP (1) JP2009535430A (de)
AU (1) AU2007248059A1 (de)
CA (1) CA2649894A1 (de)
WO (1) WO2007131041A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008286A (es) * 2007-02-02 2009-08-12 Pfizer Prod Inc Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides.
CN101616925B (zh) 2007-02-02 2012-05-23 辉瑞产品公司 三环化合物及其作为糖皮质激素受体调节剂的用途
EP3335043B1 (de) 2015-08-13 2021-03-31 Corcept Therapeutics, Inc. Verfahren zur differentiellen diagnose des acth-abhängigen cushing-syndroms
EP3402812B1 (de) * 2016-01-11 2024-03-27 Dignity Health Modulatoren mit zinkaktiviertem kationkanal
CN115053861A (zh) * 2022-06-30 2022-09-16 南方医科大学南方医院 一种基于免疫激活的精神分裂症动物模型的构建方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017779A1 (en) * 1997-10-06 1999-04-15 The Board Of Trustees Of Leland Stanford Jr. University Methods for treating psychosis associated with glucocorticoid related dysfunction
WO2003043640A2 (en) * 2001-11-23 2003-05-30 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319563T3 (es) * 2001-10-26 2009-05-08 N.V. Organon Uso de (11beta, 17beta)-11-(1.3-benzodioxol-5-il)-17-hidroxi-17-(1-propinil)estra-4,9-dien-3-ona para el tratamiento del trastorno por depresion mayor.
US8450379B2 (en) * 2002-11-05 2013-05-28 Corcept Therapeutics, Inc. Methods for treating migraine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017779A1 (en) * 1997-10-06 1999-04-15 The Board Of Trustees Of Leland Stanford Jr. University Methods for treating psychosis associated with glucocorticoid related dysfunction
WO2003043640A2 (en) * 2001-11-23 2003-05-30 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BELANOFF JOSEPH K ET AL: "An open label trial of C-1073 (mifepristone) for psychotic major depression.", 1 September 2002, BIOLOGICAL PSYCHIATRY 1 SEP 2002 LNKD- PUBMED:12242054, VOL. 52, NR. 5, PAGE(S) 386 - 392, ISSN: 0006-3223, XP002588309 *
CAPURON L ET AL: "Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.", May 2000, JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY MAY 2000 LNKD- PUBMED:10811680, VOL. 18, NR. 10, PAGE(S) 2143 - 2151, ISSN: 0732-183X, XP002588310 *
CAPURON LUCILE ET AL: "Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.", May 2004, BRAIN, BEHAVIOR, AND IMMUNITY MAY 2004 LNKD- PUBMED:15050647, VOL. 18, NR. 3, PAGE(S) 205 - 213, ISSN: 0889-1591, XP002588311 *
MAES M ET AL: "Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy.", February 2001, NEUROPSYCHOPHARMACOLOGY : OFFICIAL PUBLICATION OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY FEB 2001 LNKD- PUBMED:11120395, VOL. 24, NR. 2, PAGE(S) 130 - 140, ISSN: 0893-133X, XP002588312 *

Also Published As

Publication number Publication date
AU2007248059A1 (en) 2007-11-15
CA2649894A1 (en) 2007-11-15
EP2012796A2 (de) 2009-01-14
JP2009535430A (ja) 2009-10-01
WO2007131041A2 (en) 2007-11-15
WO2007131041A3 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
HK1211889A1 (en) Therapeutic use of diaminophenothiazines
GB0625659D0 (en) Therapeutic compounds and their use
GB0719803D0 (en) Therapeutic compounds and their use
GB0719644D0 (en) Therapeutic compounds and their use
GB0704753D0 (en) Preparation of a component for use in a joint
EP2180873A4 (de) Therapeutische dentale zusammensetzung und zugehörige verfahren
GB0724251D0 (en) Therapeutic compounds and their use
GB0524428D0 (en) Medicinal use of receptor ligands
GB0722680D0 (en) Therapeutic compounds and their use
GB2443336B (en) Spiruchostatin analogues and their medicinal use
HK1133597A1 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
EP1806147A4 (de) Verwendung eines immunsuppressiven rezeptors
GB0416728D0 (en) Medicinal use of receptor ligands
PL2121025T3 (pl) Sposoby i kompozycje dla dostarczania czynnika terapeutycznego
ZA201008538B (en) Treating psychological conditions using muscarinic receptor m1 antagonists
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
EP2012796A4 (de) Verwendung eines glucocorticoidrezeptor-ii-antagonisten zur behandlung von depressionen bei mit il-2 behandelten patienten
IL193118A0 (en) Soluble receptors and their use
EP2231163A4 (de) Verbindungen und ihre therapeutische anwendung
EP2067480A4 (de) Musclin-rezeptor und seine verwendung
EP2016949A4 (de) Neue verwendung von g-protein-konjugiertem rezeptor und ligand dafür
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB0705517D0 (en) Therapeutic compounds and their use
TWI371289B (en) Mixture for skin care
GB0710682D0 (en) Medicinal use of receptor ligands

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100708

17Q First examination report despatched

Effective date: 20120321

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120801